Inhibiting Effects and Mechanism of Celecoxib on Bladder Tumor
To evaluate the inhibiting effects of celecoxib (CEL), epoxidase 2 inhibitor, on bladder tumor in rat model as
prophylactic treatment or curative treatment. There were 52 rats of 20 weeks old in this research, the rates
were divided into 5 groups: Control group: Intermedium, cancerogen: 0.05%
N-butyl-N-(2,4-dihydroxybutyl)nitrous amide (BBN) group, CEL group Celebrex, selective COX-2 inhibitor
was 10μmg/kg/day, preventive CEL (CEL + BBN-P) group and theraputic CEL (BBN + CEL-C) group.
Preventive application of CEL obviously inhibited the growth of tumor, however, curative treatment even
increased the growth of tumor. The occurrence rate of bladder tumor was: Control group 0/8 (0%), BBN group
13/20 (65%), CEL group 0/8 (0%), CEL + BBN-P group 1/8 (12.5%) and BBN + CEL-C group 6/8 (75%).
Compared with BBN group, the quantity and volume of the tumor in the CEL + BBN-P group were obviously
lowered, accompanied with hyperplasia, atypical hyperplasia, papillary epithelioma and COX-2 immunostaining
greatly reduced. The volume of the tumor in curative BBN + CEL-C group reduced, however, the occurrence
rate of malignant tumor increased, and only the crowd receiving prevention and cure were with
anti-inflammatory and antioxidant effects. In conclusion, the prophylactic treatment, rather than curative
treatment, of celecoxib is with sufficient inhibiting effects to the development of bladder tumor, so as to
enhanced the potential functions of chemoprophylaxis strategy of cyclooxygenase 2 inhibiting effects.